Blue Water Acquisition Corp

Blue Water Acquisition — Clarus Therapeutics Holdings — Investor Presentation (January 2022)

27 slides from Blue Water Acquisition's investor presentation, Jan 19, 2022

  1. Slide 1: Investor Presentation January 2022

    androgen & metabolic therapies for better health Investor Presentation January 2022 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    Certain statements in this presentation constitute “forward-looking statements” for purposes of the federal securities laws. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,”

  3. Slide 3: Investment Summary

    Challenges we're anticipating Build a product accessible on all devices JATENZO® is the first & only FDA-approved oral softgel for testosterone replacement therapy (TRT) in appropriate adult men TRT is an attractive & growing market JATENZO has strong intellectual property protection: Worldwide pate

  4. Slide 4: Meet Our Leadership Team

    DR. ROBERT DUDLEY President & Chief Executive Officer RIC PETERSON Chief Financial Officer Meet Our Leadership Team STEVE BOURNE Chief Administrative Officer DR. JAY NEWMARK Chief Medical Officer JAMES HOLLOWAY SVP, Manufacturing & Supply FRANK JAEGER Chief Commercial Officer DR. ZHANNA JUMADILOVA C

  5. Slide 5: The JATENZO Opportunity

    NOC 69087-158-12 NOC 69087-237-12 JATENZO’ & JATENZO’ é (eststerone undecanoate) (testosterone undecanoate) sules nsules RX on, clarug R 20 Soft Gelatin Capsules mmruns 2 x Only a Soft Gelatin capsules mmrunset The JATENZO Opportunity clarus THERAPEUTICS @@™

  6. Slide 6: Growing Opportunity

    8.1MM TRX/YR2 ~2.2MM treated ~6MM diagnosed ~20MM affected 1. U.S. Census (2019); Int J of Clin Pract (2006); J Clin Endo Metabolism (2007); Symphony Healthcare (2014); IMS Health (2015); StrataMark survey results. 2. Data Sources: Symphony Metys Data January 2021 through December 2021. Growing Oppo

  7. Slide 7: JATENZO is First Oral T Softgel Approved by FDA

    Convenient *As demonstrated in JATENZO Phase 3 “inTUne” trial; see product labeling and J Clin Endocrinol Metab 105: 1-17, 2020. Effective* Safe* easy-to-swallow softgel taken twice daily (BID) with food dose adjustable option 87% of men achieved T levels in normal range restored T levels to mid-nor

  8. Slide 8: Current non-oral TRT treatments pose challenges for patients

    Current non-oral TRT treatments pose challenges for patients TRT Cycle of Discontinuation 1. On behalf of Clarus Therapeutics, Inc., Harris Poll conducted online survey between May 6 – June 5, 2020. 2. Data from Symphony PTD Rx claims from January 2021 to December 2021. Included approved claims only

  9. Slide 9: Beneficial Clinical Attributes of JATENZO

    Beneficial Clinical Attributes of JATENZO References: Swerdloff, RS and Dudley, RE. Ther Adv Urol 2020; 12: 1-16. Swerdloff, RS, et al. J Clin Endocrinol Metab 2020:105: 1-17. Increases free T & improves classic symptoms associated with hypogonadism

  10. Slide 10: JATENZO Safety Profile

    Most common adverse events (AEs) were: headache (4.8%), increased hematocrit (4.8%), hypertension (3.6%), decreased HDL cholesterol (3.0%), & nausea (2.4%)*, 1 JATENZO not associated with:2 Liver toxicity Prostate disease Adverse changes in CV risk biomarkers [hs-CRP, LpPLA2, Lp(a)] Clinically signi

  11. Slide 11: Maximizing JATENZO's Commercial Potential

    Maximizing JATENZO's Commercial Potential

  12. Slide 12: Poised to Accelerate JATENZO Growth

    60 Clinical Sales Specialists cover ~80% of TRT market prescriptions Poised to Accelerate JATENZO Growth PCPs, UROs, & ENDOs targeting top deciles HCP education & patient advertising drive awareness Corporate Account Directors focused on expanding payer coverage NOTE: Data from Symphony PTD Rx claim

  13. Slide 13: DTC is Key to Drive JATENZO Demand

    dtc is key DTC is Key to Drive JATENZO Demand Patient awareness Direct-to-consumer advertising Patient demand i-- i--

  14. Slide 14: Competitive & Affordable Coverage

    Competitive & Affordable Coverage *Data sources: Competitive data using MMIT (as of 8/26/2021) Payer Coverage Across All Channels* * Payer channels include Commercial, Medicare Part D, Medicaid, & Health Exchanges Payers reimburse brands

  15. Slide 15: Sales Force Expansion

    Sales Force Expansion Flexibility to expand sales force for greater reach & frequency based on JATENZO performance Increasing HCP awareness

  16. Slide 16: Patient-focused HUB Supports Journey

    from beginning . . . . . . . . . . . .. . . . . to JATENZO in patient’s hands Patient-focused "HUB" Supports Journey

  17. Slide 17: HUB Designed to Drive JATENZO Demand

    Find-a-Doc Targeted HCPs Clarus expanded sales force increases reach & frequency Directly ships to patient Patient HUB service Patient sees JATENZO DTC Patient visits JATENZO website Telemedicine HUB Designed to Drive JATENZO Demand Patient easily reorders JATENZO Patient satisfied

  18. Slide 18: Growth Opportunities

    Growth Opportunities |

  19. Slide 19: 3-Part Growth Strategy

    3-Part Growth Strategy JATENZO Life-Cycle Management Once-Daily - hypogonadism (8.1MM TRx/yr) F-T-M transgender (700K males)1 Chronic Kidney Disease (>2MM hypogonadal men)2 CLAR-121 (Testosterone + Anastrozole) Inflammatory breast disease; breast cancer* CLAR-222 (CoQ10 + Caspofungin) Primary & seco

  20. Slide 20: CLAR-121 (Testosterone + Anastrozole)

    CLAR-121 (Testosterone + Anastrozole) Proprietary asset for certain forms of breast disease/breast cancer MOA: activates AR-dependent anti-inflammatory mechanism(s) in breast tissue Painful, debilitating inflammation of breast tissue (L) No effective pharmaceutical intervention; often results in dis

  21. Slide 21: CLAR-222 (CoQ10 + Caspofungin)

    dtc is key CLAR -222 (CoQ10* + Caspofungin) In-licensed from McGill University Worldwide IP & marketing rights Upfront, success-based milestones & royalty payments CoQ10 is natural coenzyme vital for mitochondrial function; caspofungin is FDA-approved antifungal drug Extensive preclinical proof-of-c

  22. Slide 22: Pipeline of Assets & Timelines

    Pipeline of Assets & Timelines R&D Program Description Clinical Development Phase Projected Initiation JATENZO: CKD Treatment of hypogonadal men with chronic kidney disease* Phase 4** 1H 2022 Once daily (QD) oral TU Treatment of male hypogonadism Phase 2 2H 2022 JATENZO: male transgender T therapy f

  23. Slide 23: Strong IP & Exclusivity Pathways

    Strong IP & Exclusivity Pathways CLAR-121 & CLAR-222 Clear pathway to issued IP & market exclusivity Patent applications pending in U.S. & major non-U.S. pharma markets Potential five-year Hatch-Waxman market exclusivity upon FDA approval Potential seven-year orphan drug market exclusivity upon FDA

  24. Slide 24: Financial Highlights

    My HoLDIng \ oe Financial Highlights arus THERAPEUTICS «Se

  25. Slide 25: Financial Highlights

    Financial Highlights Revenue $9.4MM Gross profit margin 84.8% Operating expenses $40.4MM Outstanding shares 9.2MM Current cash & cash equivalents $22.0MM For the 9 months ended 9/30/21

  26. Slide 26: Key Takeaways

    Key Takeaways Experienced leadership team has extensive, relevant backgrounds & exceptional track record commercializing innovative therapies in our target markets JATENZO: is first-in-class FDA-approved oral softgel for attractive & growing TRT market has labeling expansion opportunities has patent

  27. Slide 27: androgen & metabolic therapies for better health

    androgen & metabolic therapies for better health Investor Presentation January 2022

Clarus Therapeutics Holdings — Investor Presentation (January 2022) on 6ix